TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Sunday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

Shares of TXMD opened at $1.61 on Friday. TherapeuticsMD has a 52 week low of $1.61 and a 52 week high of $4.35. The stock has a 50 day moving average price of $2.00 and a two-hundred day moving average price of $2.18.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.07) EPS for the quarter. The company had revenue of $0.31 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new position in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned about 0.21% of TherapeuticsMD as of its most recent SEC filing. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.